Related references
Note: Only part of the references are listed.Modulation of RNA Splicing Enhances Response to BCL2 Inhibition in Acute Myeloid Leukemia
Eric Wang et al.
BLOOD (2021)
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3
Rahul S. Bhansali et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study.
Mitesh J. Borad et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells
Brianna Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors
Csaba Weber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells
Ariadna Recasens et al.
CELL DEATH DISCOVERY (2021)
DYRK1a mediates BAFF-induced noncanonical NF-κB activation to promote autoimmunity and B-cell leukemogenesis
Yanchuan Li et al.
BLOOD (2021)
DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma
Charlotte Ellen Martin et al.
EXPERIMENTAL CELL RESEARCH (2021)
DYRK1A phosphorylates MEF2D and decreases its transcriptional activity
Pin Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B
David Lee Walmsley et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors
Scott H. Henderson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR
Pengshan Zhang et al.
CELL DEATH & DISEASE (2021)
Alternative splicing and cancer: a systematic review
Yuanjiao Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A
Chao Zhao et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2020)
FOXO transcription factor family in cancer and metastasis
Yannasittha Jiramongkol et al.
CANCER AND METASTASIS REVIEWS (2020)
Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer
Saleh A. Almatroodi et al.
MOLECULES (2020)
Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches
Hye Ree Yoon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Pharmacological effects of harmine and its derivatives: a review
Liang Zhang et al.
ARCHIVES OF PHARMACAL RESEARCH (2020)
How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine
Anne Wurzlbauer et al.
MOLECULES (2020)
DYRK1A Is Required to Alleviate Replication Stress in KMT2A-Rearranged Acute Lymphoblastic Leukemia
Christian Hurtz et al.
BLOOD (2020)
DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
Yangling Li et al.
CANCER BIOLOGY & MEDICINE (2020)
DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in part through interaction with RNF169
Vijay R. Menon et al.
CELL CYCLE (2019)
New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis
Helmi Tazarki et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
A complex between DYRK1A and DCAF7 phosphorylates the C-terminal domain of RNA polymerase II to promote myogenesis
Dan Yu et al.
NUCLEIC ACIDS RESEARCH (2019)
Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence
Xiuhua Xu et al.
CELL DEATH & DISEASE (2019)
Vascular defects of DYRK1A knockouts are ameliorated by modulating calcium signaling in zebrafish
Hyun-Ju Cho et al.
DISEASE MODELS & MECHANISMS (2019)
The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair
Steven E. Guard et al.
SCIENTIFIC REPORTS (2019)
A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response
Julia Roewenstrunk et al.
SCIENTIFIC REPORTS (2019)
DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291
Yang-ling Li et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth
Jeroni Luna et al.
GUT (2019)
Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one, a Promising Inhibitor of DYRK1A
Corinne Fruit et al.
PHARMACEUTICALS (2019)
A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy
Walter Becker
FEBS JOURNAL (2018)
Green tea extracts for the prevention of metachronous colorectal polyps among patients who underwent endoscopic removal of colorectal adenomas: A randomized clinical trial
Cheol Min Shin et al.
CLINICAL NUTRITION (2018)
Visualization and quantification of dynamic STAT3 homodimerization in living cells using homoFluoppi
Yusuke Okada et al.
SCIENTIFIC REPORTS (2018)
DYRK1A Kinase Positively Regulates Angiogenic Responses in Endothelial Cells
Esteban J. Rozen et al.
CELL REPORTS (2018)
MuvB: A Key to Cell Cycle Control in Ovarian Cancer
Audra N. Iness et al.
FRONTIERS IN ONCOLOGY (2018)
Meridianin C inhibits the growth of YD-10B human tongue cancer cells through macropinocytosis and the down-regulation of Dickkopf-related protein-3
Nam-Sook Park et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Development of Kinase Inhibitors via Metal-Catalyzed C-H Arylation of 8-Alkyl-thiazolo[5,4-f]-quinazolin-9-ones Designed by Fragment- Growing Studies
Florence Couly et al.
MOLECULES (2018)
Phase-separation mechanism for C-terminal hyperphosphorylation of RNA polymerase II
Huasong Lu et al.
NATURE (2018)
Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer
Hyun Myong Kim et al.
ANTICANCER RESEARCH (2018)
DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B
Mina Yousefelahiyeh et al.
PLOS ONE (2018)
Green tea extract for prevention of prostate cancer progression in patients on active surveillance
Nagi B. Kumar et al.
Oncotarget (2018)
DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome
Anis Feki et al.
BRAIN SCIENCES (2018)
NOTCH3 expression is linked to breast cancer seeding and distant metastasis
Alexey A. Leontovich et al.
BREAST CANCER RESEARCH (2018)
Ubiquitin ligases in oncogenic transformation and cancer therapy
Daniela Senft et al.
NATURE REVIEWS CANCER (2018)
A Systematic Analysis of Negative Growth Control Implicates the DREAM Complex in Cancer Cell Dormancy
James MacDonald et al.
MOLECULAR CANCER RESEARCH (2017)
Cancer stem cells revisited
Eduard Batlle et al.
NATURE MEDICINE (2017)
Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D
Pin Wang et al.
SCIENTIFIC REPORTS (2017)
Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition
Balazs Balint et al.
CHEMMEDCHEM (2017)
E3 Ligase SCFβTrCP-induced DYRK1A Protein Degradation Is Essential for Cell Cycle Progression in HEK293 Cells
Qiang Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
An ID2-dependent mechanism for VHL inactivation in cancer
Sang Bae Lee et al.
NATURE (2016)
Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis
Pin Wu et al.
ONCOTARGET (2016)
A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma
Aneesha Radhakrishnan et al.
SCIENTIFIC REPORTS (2016)
Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson's Disease?
Atbin Djamshidian et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2016)
DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model
Nobuhiro Kurabayashi et al.
EMBO REPORTS (2015)
DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies
Jianling Ji et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2015)
Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice
Gaelle Naert et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2015)
Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE
Nana Jin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3
Benjamin J. Thompson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro
Severine Coutadeur et al.
JOURNAL OF NEUROCHEMISTRY (2015)
Chromatin-wide Profiling of DYRK1A Reveals a Role as a Gene-Specific RNA Polymerase II CTD Kinase
Chiara Di Vona et al.
MOLECULAR CELL (2015)
The calcineurin/NFAT pathway is activated in diagnostic breast cancer cases and is essential to survival and metastasis of mammary cancer cells
C. Tran Quang et al.
CELL DEATH & DISEASE (2015)
Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages
Jin Jin et al.
NATURE COMMUNICATIONS (2015)
Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors
Katharina Rueben et al.
PLOS ONE (2015)
The Down syndrome-related protein kinase DYRK1A phosphorylates p27Kip1 and Cyclin D1 and induces cell cycle exit and neuronal differentiation
Ulf Soppa et al.
CELL CYCLE (2014)
Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia
L. R. Martins et al.
LEUKEMIA (2014)
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling
F. Buontempo et al.
LEUKEMIA (2014)
Alkaloids from Marine Invertebrates as Important Leads for Anticancer Drugs Discovery and Development
Concetta Imperatore et al.
MOLECULES (2014)
Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis
Marie Jarry et al.
NEURO-ONCOLOGY (2014)
Tumor Suppressor DYRK1A Effects on Proliferation and Chemoresistance of AML Cells by Downregulating c-Myc
Qiang Liu et al.
PLOS ONE (2014)
Requirement of MEF2A, C, and D for skeletal muscle regeneration
Ning Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: Development of chemical probe ML315
Thomas C. Coombs et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth
Natividad Pozo et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity
Laura Quotti Tubi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Dosage of Dyrk1a Shifts Cells within a p21-Cyclin D1 Signaling Map to Control the Decision to Enter the Cell Cycle
Jia-Yun Chen et al.
MOLECULAR CELL (2013)
CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway
R. C. Prins et al.
LEUKEMIA (2013)
Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition
Meera Soundararajan et al.
STRUCTURE (2013)
REST: an oncogene or a tumor suppressor?
Sara Negrini et al.
TRENDS IN CELL BIOLOGY (2013)
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
Carolina Navas et al.
CANCER CELL (2012)
Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Modulates Serine/Arginine-rich Protein 55 (SRp55)-promoted Tau Exon 10 Inclusion
Xiaomin Yin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome
Sebastien Malinge et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Role and Regulation of STAT3 Phosphorylation at Ser727 in Melanocytes and Melanoma Cells
Masanobu Sakaguchi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A
Shaohong Ding et al.
NEUROBIOLOGY OF AGING (2012)
REST Regulates Oncogenic Properties of Glioblastoma Stem Cells
Mohamed M. Kamal et al.
STEM CELLS (2012)
DYRK1A binds to an evolutionarily conserved WD40-repeat protein WDR68 and induces its nuclear translocation
Yoshihiko Miyata et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly
Larisa Litovchick et al.
GENES & DEVELOPMENT (2011)
Splice Variants of the Dual Specificity Tyrosine Phosphorylation-regulated Kinase 4 (DYRK4) Differ in Their Subcellular Localization and Catalytic Activity
Chrisovalantis Papadopoulos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
REST Regulates DYRK1A Transcription in a Negative Feedback Loop
Mei Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome
Jerzy Wegiel et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2011)
FGF-2 Regulates Cell Proliferation, Migration, and Angiogenesis through an NDY1/KDM2B-miR-101-EZH2 Pathway
Filippos Kottakis et al.
MOLECULAR CELL (2011)
STAT3 SIGNALING: Anticancer Strategies and Challenges
Paul A. Johnston et al.
MOLECULAR INTERVENTIONS (2011)
Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A
Wei Qian et al.
NUCLEIC ACIDS RESEARCH (2011)
CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy
Adam Siddiqui-Jain et al.
CANCER RESEARCH (2010)
Regulated Segregation of Kinase Dyrk1A during Asymmetric Neural Stem Cell Division Is Critical for EGFR-Mediated Biased Signaling
Sacri R. Ferron et al.
CELL STEM CELL (2010)
Natural Polyphenols that Display Anticancer Properties through Inhibition of Kinase Activity
D. Lamoral-Theys et al.
CURRENT MEDICINAL CHEMISTRY (2010)
ATM Augments Nuclear Stabilization of DYRK2 by Inhibiting MDM2 in the Apoptotic Response to DNA Damage
Naoe Taira et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
DYRK1A and DYRK3 Promote Cell Survival through Phosphorylation and Activation of SIRT1
Xiumei Guo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Direct Association of Sprouty-related Protein with an EVH1 Domain (SPRED) 1 or SPRED2 with DYRK1A Modifies Substrate/Kinase Interactions
Dan Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Dyrk1A Phosphorylates p53 and Inhibits Proliferation of Embryonic Neuronal Cells
Joongkyu Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Characterization of a Domain that Transiently Converts Class 2 DYRKs into Intramolecular Tyrosine Kinases
Ross Kinstrie et al.
SCIENCE SIGNALING (2010)
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1
Kwan-Hyuck Baek et al.
NATURE (2009)
DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome
Claudia Canzonetta et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
In-vitro antiproliferative activities and kinase inhibitory potencies of meridianin derivatives
Emilie Rossignol et al.
ANTI-CANCER DRUGS (2008)
Lamellarins and related pyrrole-derived alkaloids from marine organisms
Hui Fan et al.
CHEMICAL REVIEWS (2008)
Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome
Jianhua Shi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
SCFβ-TRCP controls oncogenic transformation and neural differentiation through REST degradation
Thomas F. Westbrook et al.
NATURE (2008)
Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis
K. S. Chan et al.
ONCOGENE (2008)
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21
Joseph R. Arron et al.
NATURE (2006)
Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions
Weihong Yin et al.
MOLECULAR CANCER (2006)
NFAT proteins: Key regulators of T-cell development and function
F Macian
NATURE REVIEWS IMMUNOLOGY (2005)
DYRK1A accumulates in splicing speckles through a novel targeting signal and induces speckle disassembly
M Alvarez et al.
JOURNAL OF CELL SCIENCE (2003)
FOXO forkhead transcription factors induce G2-M checkpoint in response to oxidative stress
Y Furukawa-Hibi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The role of NFAT transcription factors in integrin-mediated carcinoma invasion
S Jauliac et al.
NATURE CELL BIOLOGY (2002)
Simultaneous tyrosine and serine phosphorylation of STAT3 transcription factor is involved in Rho A GTPase oncogenic transformation
S Aznar et al.
MOLECULAR BIOLOGY OF THE CELL (2001)
Myocyte enhancer factor 2A and 2D undergo phosphorylation and caspase-mediated degradation during apoptosis of rat cerebellar granule neurons
MT Li et al.
JOURNAL OF NEUROSCIENCE (2001)
Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome
X Altafaj et al.
HUMAN MOLECULAR GENETICS (2001)
The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site
YL Woods et al.
BIOCHEMICAL JOURNAL (2001)
Share Paper
